This fact sheet describes patient-directed strategies for finding clinical trials.
An overview of the potential immune-related adverse events that can arise from treatment with checkpoint inhibitors.
Research is still needed to explore the association between cancer chemotherapeutics and rheumatoid arthritis.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.
Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into the calculation of neutropenia risk.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.
In a recent analysis of VA hospital records, more than half of all oncologic errors and adverse events were attributed to uncoordinated cancer care.
Traditional genetic testing historically included the sequential analysis of single and generally well-described genes involved in heritable cancers.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Researchers are promoting physician and patient awareness about the potential tie between depression and certain therapies.
Cancer therapy is a continually evolving field, as researchers strive to determine the most effective methods of treating this complex disease.
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
Recurrence of GA following cancer treatment should signal the possibility of cancer recurrence.
TNFi treatment is not associated with increased risk for cancer recurrence in patients with rheumatoid arthritis
Tumor cell lines derived from single cells and curated at different reference labs have quietly evolved in vitro, accumulating distinct genomic aberrations.
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Though it is clear that cancer is associated with an extreme financial burden, the extent of the burden varies widely.
There is concern that added nitrates and nitrites are associated with an increased risk of cancer, but epidemiologic data have been inconclusive thus far.
A meta-analysis of 20 randomized clinical trials found that men may infer a greater benefit from immune checkpoint inhibition.
From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.
There has been little historical evidence to show whether modifying per capita use of alcohol and/or tobacco could affect the cancer mortality rate.
The subtle differences within subsets of populations could tell researchers more about how some cancers affect distinct racial or ethnic populations across a heterogeneous group of minorities.
The mechanisms that drive this benefit are not well-understood, and it is believed that the benefit is not just a result of reducing risk factors such as body weight.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Close postmarketing monitoring will be especially crucial for drugs approved with a breakthrough therapy designation, as many of them were given a pass on the basis of a single pivotal trial.
Drug developers relying on CRISPR-Cas9 platforms for the creation of gene therapies saw their shares slide when it was revealed that the technique may inadvertently cause disruptions of larger chunks of DNA than previously thought.
Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC